前列地尔与羟苯磺酸钙联合治疗慢性肾衰竭的疗效观察  

Observation on Efficacy of Alprostadil Combined with Calcium Dobesilate in Treatment of Chronic Renal Failure

作　　者：王学珍[1] 魏晓颖[1] 

机构地区：[1]商丘市第一人民医院肾病内科,河南商丘476100

出　　处：《中国医院用药评价与分析》2017年第9期1223-1225,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨前列地尔与羟苯磺酸钙联合治疗慢性肾衰竭的临床疗效及安全性。方法:选取2013年5月—2016年7月商丘市第一人民医院收治的慢性肾衰竭患者185例,采用随机数字表法分为对照组(93例)和观察组(92例)。对照组患者采用常规治疗,观察组患者在对照组基础上加用前列地尔与羟苯磺酸钙联合治疗。比较两组患者治疗前后的肾功能、血液指标及不良反应发生情况。结果:与治疗前比较,治疗后两组患者的血尿素氮(BUN)、血肌酐(Scr)、尿酸(UA)及观察组患者24 h尿蛋白水平均明显降低,两组患者内生肌酐清除率(Ccr)明显升高,且观察组患者的BUN、Scr、UA、24 h尿蛋白水平明显低于对照组,Ccr水平明显高于对照组,差异均有统计学意义(P<0.05);两组患者的全血低切黏度、全血高切黏度、血浆黏度、三酰甘油(TG)及观察组患者总胆固醇(TC)水平均明显降低,且观察组患者的全血低切黏、全血高切黏度、血浆黏度、TC、TG水平明显低于对照组,差异均有统计学意义(P<0.05);两组患者均未发生明显不良反应。结论:前列地尔与羟苯磺酸钙联合治疗慢性肾衰竭,能显著改善患者的肾脏功能,安全性高。OBJECTIVE： To probe into the clinical efficacy and safety of alprostadil combined with calcium dobesilate in treatment of chronic renal failure. METHODS： 185 patients with chronic renal failure admitted into Shangqiu the First People＇s Hospital from May 2013 to Jul. 2016 were selected to be divided into control group（ 93cases） and observation group（ 92 cases） via the random number table. The control group received conventional treatment,while the observation group additionally received alprostadil combined with calcium dobesilate based on the control group. The renal function,blood indicators and incidence of adverse drug reactions of two groups were compared. RESULTS： Compared with before treatment,the blood urea nitrogen（ BUN）,serum creatinine（ Scr） and uric acid（ UA） of two groups and 24 h protein level of observation group decreased significantly after treatment,yet the endogenous creatinine clearance rate（ Ccr） of two groups increased significantly,and the BUN,Scr,UA and 24 h protein level of observation group were lower than those of control group,yet Ccr was higher than that of the control group,with statistically significant difference（ P〈0. 05）. The low blood viscosity,high blood viscosity,plasm viscosity,TG level of two groups and TC level of observation group decreased significantly,and the observation group was lower than those of control group,with statistically significant difference（ P〈0. 05）. There was no severe adverse drug reactions in both groups. CONCLUSIONS： Alprostadil combined with calcium dobesilate in treatment of chronic renal failure can significantly improve the renal function in patients with chronic renal failure with higher safety.

关 键 词：前列地尔 羟苯磺酸钙 慢性肾衰竭 临床应用 

分 类 号：R977[医药卫生—药品]